Investors of ARS Pharmaceuticals have a window to lead a securities fraud class action over alleged misleading statements about CVS Caremark formulary timing
Executive summary: Rosen Law Firm announced a class action lawsuit for purchasers of ARS Pharmaceuticals (SPRY) securities between March 9 and June 24, 2026, alleging securities fraud related to undisclosed risks about CVS Caremark formulary timing for the Neffy epinephrine spray. The lawsuit could result in financial liability for ARS if claims are substantiated, and highlights ongoing investor concerns about transparency in biopharma commercialization timelines, especially following the June stock drop after CVS delayed its Neffy decision.
Who is involved: ARS Pharmaceuticals (NASDAQ: SPRY), Rosen Law Firm (plaintiff counsel), investors who purchased SPRY shares during the class period, and CVS Caremark (whose formulary decision timing is central to the allegations).
Likely next: Investors have until October 5, 2026 to seek lead plaintiff status; the case will proceed if certified, with discovery and potential settlement or trial to follow.
Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of ARS Pharmaceuticals (NASDAQ: SPRY) securities between March 9 and June 24, 2026, alleging the company built analyst expectations on a July 1, 2026 CVS Caremark coverage timeline that was never disclosed as at risk of slipping to January 2027. The lawsuit seeks to represent investors who suffered losses during the class period. This follows prior warnings and a stock collapse in June after CVS delayed its decision on the epinephrine spray Neffy. The case centers on whether ARS omitted material risks about formulary approval timing.
What's next — scenarios
Legal Dismissal / Rapid Settlement (55%)
Stock price stabilizes as litigation risk is capped or removed through a quick settlement.
- Motion to dismiss granted by court
- Settlement agreement announced without major discovery phase
Protracted Litigation & Discovery (30%)
Sustained downward pressure on SPRY stock due to legal expenses and uncertainty.
- Class certification approved
- Internal company communications regarding CVS timelines leaked or subpoenaed
Regulatory Escalation (15%)
Institutional divestment as SEC or other regulators open formal inquiries into disclosure practices.
- SEC filing regarding non-disclosure
- Formal investigation announcement regarding Neffy marketing or formulary claims
What to watch
- Court schedule for motions to dismiss (Next 60 days)
- ARS Pharmaceuticals quarterly earnings call regarding legal reserves (Next 90 days)
- Any official update from CVS Caremark regarding Neffy formulary status (Next 30 days)
Timeline
- — SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit (PR Newswire)
- — ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results (GlobeNewswire)
- — ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEO (Yahoo Finance)
- — INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY (PR Newswire)
- — ARS Pharma Collapses After CVS Punts Its Epinephrine Spray Decision To January (Investors.com (Yahoo Finance))
Analysis — what this means
Likely next events
- October 5, 2026: Deadline for investors to file motions for lead plaintiff in the ARS Pharmaceuticals class action
- Q3 2026: Potential ARS update on Neffy commercialization progress amid ongoing litigation
Sectors affected
- Biopharmaceuticals
- Allergy and anaphylaxis therapeutics
- Nasdaq-listed healthcare stocks
Historical parallels
- Valeant Pharmaceuticals accounting scandal and stock collapse (2015)
- Biogen’s Aduhelm launch and subsequent Medicare coverage limitations (2021)
Key entities
Sources
- SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit — PR Newswire
- ARS Pharma Collapses After CVS Punts Its Epinephrine Spray Decision To January — Investors.com (Yahoo Finance)
- ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEO — Yahoo Finance
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY — PR Newswire
- ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results — GlobeNewswire
Related cases
- ARS Pharmaceuticals faces critical deadline for investors seeking to lead securities fraud class action litigation
- Rosen Law Firm reminds SPRY shareholders of October 5 lead plaintiff deadline in securities fraud class action alleging misleading CVS Caremark formulary timeline for neffy
- Investors get chance to serve as lead plaintiffs in ARS Pharmaceuticals securities fraud lawsuit
- Rosen Law Firm launches a securities fraud class action against ARS Pharmaceuticals, exposing the company to potential legal costs and share‑price pressure